Bright Minds Biosciences Announces Non-Executive Director
David Weiner, MD, brings extensive experience in the discovery and clinical development of novel therapeutics for
Globe Newswire17-02-2023, 18:52
Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma 16-10-2023, 19:21